Pharmaceutical

Pharmaceutical products are subject to an increasingly complex web of packaging and labeling regulations that vary by market, dosage form, and drug classification. From FDA requirements in the United States to EU GMP Annex 11 expectations, Health Canada guidelines, and emerging market regulations, the compliance landscape demands deep regulatory knowledge and rigorous documentation practices.

Meridan operates within a unified quality management system designed from the ground up for pharmaceutical regulatory compliance. Our quality and regulatory affairs teams maintain current knowledge of packaging regulations across major markets and work directly with customers to ensure that packaging configurations, labeling content, and serialization data meet the specific requirements of each target market. All processes are documented, validated, and audit-ready for FDA, EU, and international regulatory inspections.

The Drug Supply Chain Security Act and equivalent international regulations have fundamentally changed pharmaceutical packaging requirements, mandating unique serialization at the unit level, aggregation at each packaging hierarchy, and electronic transaction data exchange throughout the supply chain. For pharmaceutical companies managing dozens or hundreds of SKUs across multiple contract packagers, achieving consistent serialization compliance is a significant operational challenge.

Meridan has invested heavily in serialization infrastructure, deploying Optel InspectRx line-level systems and Systech UniSeries enterprise management across all facilities. Our serialization platform supports DSCSA, EU FMD, Brazil ANVISA, and other global requirements from a single, integrated architecture. We manage serial number generation, commissioning, aggregation, and regulatory reporting as a turnkey service, including direct connectivity to customer ERP systems and trading partner portals.

Pharmaceutical companies face intense pressure to compress the timeline from regulatory approval to commercial availability. Packaging is often one of the final steps before market launch, and delays in packaging development, validation, or production can directly impact revenue realization and competitive positioning. Launch timelines are further complicated by the need to coordinate packaging across multiple markets with different labeling and regulatory requirements.

Meridan maintains dedicated project management resources for new product launch programs, coordinating packaging engineering, component procurement, line qualification, and production scheduling through a structured launch readiness process. Our multi-facility footprint provides the flexibility to allocate capacity where and when it is needed, while our standardized quality system enables rapid validation and tech transfer. We routinely support accelerated launch timelines for pharmaceutical customers, including parallel workstream execution to compress the overall schedule.

Pharmaceutical supply chains are under increasing scrutiny from regulators, payers, and patients who expect uninterrupted access to critical medicines. Single points of failure in the packaging supply chain - whether from equipment breakdowns, facility disruptions, or natural events - can create stockouts that affect patient care and generate regulatory concerns.

Meridan addresses supply chain resilience through multi-facility redundancy, cross-qualification of products at backup sites, and a unified quality system that enables efficient production transfers between facilities. Our three-facility network provides geographic diversification across the United States, reducing exposure to regional disruptions. For critical products, we work with customers to establish dual-site qualification strategies that maintain validated backup packaging capability at an alternate Meridan facility.